Building an AI strategy for Canadian pharmaceutical organizations

Health Canada does not have a dedicated AI regulation for pharmaceutical companies. That gap is why a growing number of Canadian drug manufacturers, CROs, and specialty pharmacies are writing their own AI governance policies this year rather than waiting for Ottawa to catch up.

The pressure comes from two directions. Quebec's Law 25 has been in full force since September 2023, and its transfer-assessment requirements for data leaving the province are now routine in vendor onboarding. PIPEDA, Canada's federal privacy statute, still governs how personal health information moves through any AI tool touching patient data, trial records, or adverse-event reports. Neither law was written with large language models in mind. Both apply to them anyway. For a sector handling clinical trial data, patient support programs, and manufacturing records at once, the live question is not whether to use AI — most of the sector already does — but which tools can be deployed without creating a compliance problem that outlives the product launch.

The Jurisdiction Question Pharma Can't Outsource

A clinical operations director at a mid-sized Toronto-based CRO, who asked not to be named because her company's vendor negotiations are ongoing, said her legal team now asks every AI vendor the same first question, before pricing, before features. Where does the data sit, and under whose law.

That question has teeth in pharma in a way it does not in most industries. Clinical trial data falls under research ethics board oversight and, often, contractual obligations to sponsors that specify data residency. Patient support programs collect health information directly from individuals, triggering Law 25's stricter consent rules if any Quebec resident is enrolled. Manufacturing and quality records tied to drug submissions are subject to Health Canada inspection, which means a company needs to know precisely where those records have lived and who could have accessed them.

US-headquartered AI vendors complicate that picture because of the CLOUD Act, the 2018 US statute that lets American law enforcement compel US companies to produce data they control, regardless of where that data is physically stored. A pharma company does not need to believe a request is likely in order to treat the exposure as a real variable in a risk assessment. Canadian privacy lawyers have been flagging it explicitly in client memos over the past two years, according to public commentary from the Canadian Bar Association's privacy section.

"The CLOUD Act doesn't require a server to be in the US. It requires the company to be," one privacy lawyer told a CBA panel discussion on cross-border data flows.

That distinction is why procurement teams are increasingly drawing a hard line between vendors with a US corporate parent and those without one, treating it as a structural question rather than a feature comparison.

What a Canadian AI Platform Actually Changes

Sovereign Canadian AI platforms have entered pharma procurement conversations over the past 18 months, not as a patriotic preference but as an answer to a specific legal exposure.

Augure is one of a small number of Canadian AI platform providers positioning explicitly around that gap. The company has no US corporate parent and no US investors, and says customer conversations, documents, and AI inference are never handled by providers under US jurisdiction — a structural claim, not a marketing adjective, and one that means the CLOUD Act's reach over US-controlled providers does not extend to that customer content. Customer data is stored in Canada. Inference runs on Canadian infrastructure for some model tiers, with vetted EU partners handling others and serving as failover under zero-data-retention agreements, and customer content is never routed to the United States. Payment processing and email delivery still touch US-based networks, which Augure discloses in its privacy policy rather than omitting — a detail that matters for any pharma company running its own Law 25 transfer assessment, since that analysis requires knowing exactly which data categories cross a border and why.

For a pharma compliance officer, that disclosure is the actual deliverable, more than the residency claim itself. A vendor that names its sub-processors and explains which flows exist gives a legal team something to assess. A vendor that simply asserts it is compliant gives them nothing to check.

Augure is not the only Canadian option pharma companies are evaluating. Procurement lists reviewed informally for this piece also included Cohere's enterprise offerings and a handful of smaller Canadian document-review startups serving regulated industries specifically. What distinguishes the pharma use case is the combination of requirements: persistent memory for long-running research projects, a private knowledge base that does not leak into a shared training set, and contract review tooling for the licensing and supply agreements pharma companies sign constantly with manufacturers, distributors, and CROs.

Building the Internal Policy, Not Just Picking the Tool

Vendor selection is the easy half of the problem. The harder half is internal governance — who in a pharma organization is allowed to put what kind of data into an AI tool, and under what review.

Most pharma companies interviewed for pieces like this one over the past year describe a tiered approach, even if none call it that formally:

• Public or already-published information (regulatory filings, competitor analysis, literature review) goes into general-purpose AI tools with few restrictions.
• De-identified clinical or operational data requires a documented data processing agreement and, often, sign-off from a privacy officer before any AI tool touches it.
• Identifiable patient data, active trial data, and anything tied to a drug submission in progress typically requires either an internal AI deployment, a vendor with specific regulatory attestations, or an outright prohibition pending further review.

That third tier is where most of the actual friction lives, and where companies spend real negotiating time with vendors on data processing addenda, audit rights, and breach notification timelines — the contractual mechanics that make a privacy law's requirements enforceable rather than aspirational.

A compliance lead at a Montreal-based specialty pharmacy chain, speaking on background, said her biggest internal fight this year was not choosing a vendor but getting clinical staff to stop using personal ChatGPT accounts for drafting patient correspondence. The AI strategy document that resulted runs four pages and spends half of them on what employees should not do, rather than what the company has adopted.

Regulatory Timeline Still Open

Health Canada has signaled, in public remarks and in its ongoing work on software as a medical device, that AI-specific guidance for pharmaceutical and health-adjacent uses is coming, though no draft has been published as of this writing. The federal Artificial Intelligence and Data Act, tabled in 2022 as part of Bill C-27, died when Parliament prorogued in January 2025 and has not been reintroduced in its original form, leaving a gap that provincial privacy law and sector-specific guidance are filling unevenly.

That leaves pharma companies building governance ahead of the regulator rather than in response to it — uncomfortable, several people interviewed for this piece said, but not unusual for an industry used to Good Manufacturing Practice and Good Clinical Practice frameworks that predate most of the digital tools it now relies on. The instinct to document everything, assume audit, and assign accountability by role rather than by tool is already baked into pharma culture. Applying that instinct to AI vendor selection is turning out to be less of a leap than building the instinct from scratch would have been.

What is less settled is whether "Canadian" as a procurement criterion hardens into a formal RFP requirement, the way data residency clauses already are for cloud infrastructure, or stays an informal preference that varies by company and by how recently its legal team read about the CLOUD Act. Right now it is the second thing. That could change with one high-profile enforcement action or one bad headline about a vendor's data handling, and nobody interviewed for this piece was willing to bet on which direction it moves first.

Augure's product pages, including pricing for the Legal product used for contract review and NDA triage, are at augureai.ca for companies doing their own comparison.